Evaluating eligibility criteria of oncology trials using real-world data and AI
Top Cited Papers
- 7 April 2021
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 592 (7855) , 629-633
Abstract
There is a growing focus on making clinical trials more inclusive but the design of trial eligibility criteria remains challenging1,2,3. Here we systematically evaluate the effect of different eligibility criteria on cancer trial populations and outcomes with real-world data using the computational framework of Trial Pathfinder. We apply Trial Pathfinder to emulate completed trials of advanced non-small-cell lung cancer using data from a nationwide database of electronic health records comprising 61,094 patients with advanced non-small-cell lung cancer. Our analyses reveal that many common criteria, including exclusions based on several laboratory values, had a minimal effect on the trial hazard ratios. When we used a data-driven approach to broaden restrictive criteria, the pool of eligible patients more than doubled on average and the hazard ratio of the overall survival decreased by an average of 0.05. This suggests that many patients who were not eligible under the original trial criteria could potentially benefit from the treatments. We further support our findings through analyses of other types of cancer and patient-safety data from diverse clinical trials. Our data-driven methodology for evaluating eligibility criteria can facilitate the design of more-inclusive trials while maintaining safeguards for patient safety.Keywords
This publication has 40 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Modernizing Eligibility Criteria for Molecularly Driven TrialsJournal of Clinical Oncology, 2015
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trialThe Lancet Oncology, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Increasing the efficiency of trial-patient matching: automated clinical trial eligibility Pre-screening for pediatric oncology patientsBMC Medical Informatics and Decision Making, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical JournalsJAMA, 2007
- A Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical TrialsJournal of Clinical Epidemiology, 1998